Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
Reena Khanna(University of Toronto), Brian G. Feagan(Western University), Séverine Vermeire(KU Leuven), Joan C. Morris(Robarts Clinical Trials), Alain Bitton(McGill University Health Centre), William J. Sandborn(University of San Diego), Margaret K. Vandervoort(Western University), Geert D’Haens(Amsterdam University Medical Centers), Brian Bressler(University of British Columbia), Larry Stitt(Western University), Guangyong Zou(Western University), Barrett G. Levesque(University of California San Diego), Gordon R. Greenberg(University of Toronto), Allan Donner(Western University), Pierre Paré(Université Laval), Donald MacIntosh(Dalhousie University), Remo Panaccione(University of Calgary)
Cited by 462
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k